The EFFECTS of GAMBIR CATECHIN (UNCARIA GAMBIR ROXB) SUPPLEMENTATION on COGNITIVE FUNCTION, EXPRESSION of APP, MAPT, BDNF, IL-10, TGF-Β GENES, and PLASMA MDA LEVELS in the ELDERLY.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-01

Study Completion Date

2024-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective The primary objective of this clinical trial is to investigate the effects of gambir catechin administration on cognitive function, the expression of amyloid precursor protein (APP), microtubule-associated protein tau (MAPT), brain-derived neurotrophic factor (BDNF), interleukin-10 (IL-10), transforming growth factor beta (TGF-beta), and plasma malondialdehyde (MDA) levels in elderly individuals.

Research Questions

The primary research questions to be addressed in this study are as follows:

1. Does the administration of gambir catechin (Uncaria gambir Roxb) improve cognitive function as measured by the Montreal Cognitive Assessment-Indonesia (MoCA-INA) in the elderly after 12 weeks of intervention?
2. Does the administration of gambir catechin (Uncaria gambir Roxb) affect the expression of APP, MAPT, BDNF, IL-10, and TGF-beta genes in the elderly after 12 weeks of intervention?
3. Does the administration of gambir catechin (Uncaria gambir Roxb) influence plasma MDA levels in the elderly after 12 weeks of intervention? Methodology

To answer these questions, researchers will compare the effects of gambir catechin with a placebo (an inert substance). This double-blind, randomized controlled trial will involve:

* Participant Recruitment: Elderly individuals will be recruited and randomly assigned to either the gambir catechin or placebo group.
* Intervention: Participants will receive daily doses of gambir catechin or a placebo for 12 weeks.
* Assessments: Cognitive function, gene expression, and plasma MDA levels will be assessed at baseline and after 12 weeks of intervention.
* Data Analysis: The collected data will be analyzed using appropriate statistical methods to determine the effects of gambir catechin.

Participant Involvement

Participants will be required to:

* Consume the assigned supplement (gambir catechin or placebo) daily.
* Attend regular follow-up visits at the research center.
* Report any adverse events or changes in their health during the study period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults

NCT02446314

Cognitive Decline

COMPLETED NA

Nutraceutical Effects on Long-Term Memory

NCT01963767

Aging

COMPLETED PHASE2

The Effect of Dietary Strawberry Supplementation on Older Adults

NCT02051140

Aging Age-related Memory Disorders

COMPLETED NA

Efficacy and Safety of Catechin High Contain Greentea Extract on Improvement of Cognitive Function

NCT03826017

Cognitive Function

COMPLETED NA

A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Mulberry Fruit Extract

NCT01230268

Oxidative Stress

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Effects of Gambier Catechin (Uncaria gambir Roxb) Supplementation on Cognitive Function, APP, MAPT, BDNF, IL-10, TGF-β Gene Expression, and Plasma MDA Levels in the Elderly

1. Background Problem: The increasing prevalence of mild cognitive impairment among the elderly and its impact on their quality of life.

Research Gap: A lack of research on the utilization of local plants, specifically catechin, an active compound found in gambier leaves, which possesses antioxidant and anti-inflammatory properties and may enhance cognitive function in the elderly population in Indonesia.

Research Objective: To investigate the effects of gambier catechin (Uncaria gambir Roxb) supplementation on cognitive function, APP, MAPT, BDNF, IL-10, TGF-β gene expression, and plasma MDA levels in the elderly.
2. Hypothesis

1. There is an effect of gambier catechin (Uncaria gambir Roxb) supplementation on improving cognitive function as measured by the MoCA-INA test in the elderly after 12 weeks of supplementation.
2. There is an effect of gambier catechin (Uncaria gambir Roxb) supplementation on decreasing the expression of APP, MAPT, TGF-β genes and increasing the expression of BDNF, IL-10 genes in the elderly after 12 weeks of supplementation.
3. There is an effect of gambier catechin (Uncaria gambir Roxb) supplementation on decreasing plasma MDA levels in the elderly after 12 weeks of supplementation.
3. Research Method Research Design: A randomized controlled trial (RCT) design will be used. Population and Sample:The target population for this study is the elderly aged 60 years and above with mild cognitive impairment (MoCA-INA score of 20-25) residing in Padang City, West Sumatra, Indonesia.
4. Research Procedure

1. Recruitment and Screening

1. Participants will be recruited from community centers, senior citizen clubs, and public health facilities in Padang City.
2. Eligibility criteria will include:

1. Age 60 years and above
2. Mild cognitive impairment (MoCA-INA score of 20-25)
3. No history of neurological or psychiatric disorders
4. No history of substance abuse or chronic medical conditions that may interfere with cognitive function
5. Willingness to participate in the study and provide informed consent
2. Baseline Assessments



1. Demographic information will be collected.
2. Cognitive function will be assessed using the Montreal Cognitive Assessment-Indonesia (MoCA-INA) test.
3. Blood samples will be drawn for biochemical analysis, including plasma MDA levels.
4. Genetic analysis will be conducted to assess the expression of APP, MAPT, BDNF, IL-10, and TGF-β genes.

c. Intervention
1. Participants will be randomly assigned to either the intervention or control group.
2. The intervention group will receive gambier catechin supplementation (Uncaria gambir Roxb) at a daily dose of \[Insert dosage\] for 12 weeks.
3. The control group will receive a placebo. d. Follow-up Assessments



1. Cognitive function will be reassessed using the MoCA-INA test at 12 weeks.
2. Blood samples will be drawn for biochemical analysis and genetic analysis as described in the baseline assessments.
5. Data Analysis

1. Descriptive statistics will be used to summarize demographic data, cognitive function scores, and biochemical parameters.
2. Inferential statistics, including t-tests and ANOVA, will be used to compare the differences between the intervention and control groups.
3. Correlation analysis will be conducted to examine the relationship between cognitive function, genetic expression, and plasma MDA levels.
6. Ethical Considerations

1. The study will be conducted in accordance with ethical principles and guidelines, including the Declaration of Helsinki.
2. Informed consent will be obtained from all participants.
3. Participant confidentiality will be maintained throughout the study.
4. Any adverse events will be monitored and reported.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Elderly Individuals Aged 60 Years or Older Mild Cognitive Impairment (MCI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Objective:

This clinical trial aims to investigate the effects of gambir catechin supplementation on cognitive function, and plasma levels of APP, MAPT, BDNF, IL-10, TGF-beta, and MDA in the elderly.

Research Design: A randomized controlled trial (RCT) design will be used. Population and Sample:The target population for this study is the elderly aged 60 years and above with mild cognitive impairment (MoCA-INA score of 20-25) residing in Padang City, West Sumatra, Indonesia.

Intervention

1. Participants will be randomly assigned to either the intervention or control group.
2. The intervention group will receive gambier catechin supplementation (Uncaria gambir Roxb) at a daily dose of \[224 mg\] for 12 weeks.
3. The control group will receive a placebo.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: Catechin Group Arm 2: Placebo Group

Arm 1: Catechin Group. Participants in this group received one capsule of gambir catechin daily, with a dosage of 224 mg.

Arm 2: Placebo Group. Participants in this group received one placebo capsule daily, with a dosage of 224 mg.

Group Type PLACEBO_COMPARATOR

catechin extracts (health food)

Intervention Type DIETARY_SUPPLEMENT

Type of intervention:

1. Purified gambir ≥ 90% (+)-Catechin
2. Dosage of 224 mg catechin capsule, once daily
3. Dosage of 224 mg placebo capsule, once daily
4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\"

plasebo

Intervention Type OTHER

Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.

Effects of Gambier Catechin Supplementation on Cognitive Function, APP, MAPT,

Gambir purified with a minimum of 90% (+)-Catechin content. Dosage of 224 mg catechin per capsule, once daily.

Group Type EXPERIMENTAL

catechin extracts (health food)

Intervention Type DIETARY_SUPPLEMENT

Type of intervention:

1. Purified gambir ≥ 90% (+)-Catechin
2. Dosage of 224 mg catechin capsule, once daily
3. Dosage of 224 mg placebo capsule, once daily
4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\"

plasebo

Intervention Type OTHER

Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

catechin extracts (health food)

Type of intervention:

1. Purified gambir ≥ 90% (+)-Catechin
2. Dosage of 224 mg catechin capsule, once daily
3. Dosage of 224 mg placebo capsule, once daily
4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\"

Intervention Type DIETARY_SUPPLEMENT

plasebo

Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 60 years and above
2. Mild cognitive impairment (MoCA-INA score of 20-25)
3. No history of neurological or psychiatric disorders
4. No history of substance abuse or chronic medical conditions that may interfere with cognitive function
5. Willingness to participate in the study and provide informed consent